Compare VSAT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | BMRN |
|---|---|---|
| Founded | 1986 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.4B |
| IPO Year | 1996 | 1999 |
| Metric | VSAT | BMRN |
|---|---|---|
| Price | $61.83 | $58.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 18 |
| Target Price | $59.80 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 3.0M | 2.1M |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.42 | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $5.32 | $15.02 |
| Revenue Next Year | $3.57 | $12.23 |
| P/E Ratio | ★ N/A | $106.20 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $14.00 | $49.26 |
| 52 Week High | $89.79 | $66.28 |
| Indicator | VSAT | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 63.28 |
| Support Level | $58.84 | $54.24 |
| Resistance Level | $64.98 | $61.92 |
| Average True Range (ATR) | 5.43 | 1.42 |
| MACD | -0.91 | 0.23 |
| Stochastic Oscillator | 20.24 | 78.95 |
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.